Dr. Reddy's Lab is poised to witness crosswinds from a drop in revenue from the patent expiration of Revlimid and increased ...

Dr Reddy's Laboratories (DRL) share price plunged 6.66 per cent to Rs 1,203.50 per share on the NSE during Friday after ...

NHS patients in England with newly-diagnosed multiple myeloma can be treated with Celgene’s Revlimid as maintenance therapy after a stem cell transplant, after new guidance from NICE.

Revlimid, which has arguably been the single biggest growth driver for Dr Reddy's in recent years, is set to go off patent in ...

Dr. Reddy’s is focusing on a pipeline of complex drugs, including GLP-1 (such as Semaglutide) as well as biosimilars and consumer care to offset the loss of exclusivity for its blockbuster drug ...

Sanofi SNY announced that the European Commission (“EC”) has granted marketing authorization to expand the use of its multiple myeloma (MM) drug, Sarclisa (isatuximab). With this nod, Sarclisa is now ...

The company's North American revenue has seen a decline of over 9%. One of the primary worries is the reduction in revenues ...

Indian pharmaceutical (IT) major, Dr Reddy's Laboratories, is scheduled to deliver its October-December quarterly earnings ...

Indian pharma companies like Dr Reddys, Zydus, Cipla, and Sun can sustain low double-digit EPS growth over the medium term.

While Sun Pharma continues to demonstrate strength in its branded and specialty businesses, concerns around US generics, R&D ...

Although Dr Reddy's Laboratories' Q3 earnings slightly exceeded analysts' expectations, the main point of concern was the ...

Sun Pharma's Q3 earnings may see a slight setback in margins, pressured by increased R&D expenses and a lower contribution ...